Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead

17 Oct 2026 0 comments

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

Source: NeurologyLive · Published 17 Oct 2026 · Imported 17 Oct 2026

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment